Hookipa Pharma Company Leadership
| HOOK Stock | USD 1.02 0.03 2.86% |
Hookipa Pharma's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Hookipa Pharma suggests that most insiders are panicking. Hookipa Pharma employs about 82 people. The company is managed by 16 executives with a total tenure of roughly 192 years, averaging almost 12.0 years of service per executive, having 5.13 employees per reported executive.
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
| 2025-07-22 | Mary Theresa Coelho | Disposed 13609 @ 0.92 | View |
Monitoring Hookipa Pharma's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. Hookipa Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.452) % which means that it has lost $0.452 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0579) %, meaning that it created substantial loss on money invested by shareholders. Hookipa Pharma's management efficiency ratios could be used to measure how well Hookipa Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.64. The value of Return On Capital Employed is expected to slide to -1.07. At this time, Hookipa Pharma's Liabilities And Stockholders Equity is quite stable compared to the past year. Non Current Liabilities Other is expected to rise to about 7.7 M this year, although the value of Total Current Liabilities will most likely fall to about 25.4 M.Common Stock Shares Outstanding is expected to rise to about 15.1 M this year, although the value of Net Loss will most likely fall to (61.3 M). The market capitalization of Hookipa Pharma is $12.95 Million. Roughly 87.72 (percent) of Hookipa Pharma outstanding shares are held by general public with 0.12 % owned by insiders and only 12.16 pct. by outside corporations. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 12.7 M | Current Value 10 M | Avarage Shares Outstanding 5.8 M | Quarterly Volatility 4.6 M |
Hookipa Pharma Workforce Comparison
Hookipa Pharma is one of the top stocks in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 138. Hookipa Pharma totals roughly 82.0 in number of employees claiming about 59% of equities under Health Care industry.
Hookipa Pharma Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Hookipa Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Hookipa Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Hookipa Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Matushansky Igor over a week ago Disposition of 2205 shares by Matushansky Igor of Hookipa Pharma at 2.49 subject to Rule 16b-3 | ||
Peters Malte over a month ago Disposition of 25172 shares by Peters Malte of Hookipa Pharma at 0.8217 subject to Rule 16b-3 | ||
Aldag Jorn over two months ago Acquisition by Aldag Jorn of 47824 shares of Hookipa Pharma at 3.0 subject to Rule 16b-3 | ||
Klaus Orlinger over six months ago Acquisition by Klaus Orlinger of 194200 shares of Hookipa Pharma at 1.0 subject to Rule 16b-3 | ||
Klaus Orlinger over six months ago Acquisition by Klaus Orlinger of 48350 shares of Hookipa Pharma at 1.66 subject to Rule 16b-3 | ||
Reinhard Kandera over six months ago Acquisition by Reinhard Kandera of 14056 shares of Hookipa Pharma at 3.0 subject to Rule 16b-3 | ||
Peters Malte over six months ago Acquisition by Peters Malte of 52000 shares of Hookipa Pharma at 1.01 subject to Rule 16b-3 | ||
O'neill Julie over six months ago Acquisition by Oneill Julie of 20000 shares of Hookipa Pharma subject to Rule 16b-3 |
Hookipa Pharma Notable Stakeholders
A Hookipa Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Hookipa Pharma often face trade-offs trying to please all of them. Hookipa Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Hookipa Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Daniel MD | CoFounder Board | Profile | |
| Malte MD | President CEO | Profile | |
| Mary MBA | CFO, VP | Profile | |
| Lukas Flatz | CoFounder | Profile | |
| Klaus Orlinger | Chief Officer | Profile | |
| Reinhard Kandera | CFO Director | Profile | |
| Matthew Beck | Executive Relations | Profile | |
| Mark Winderlich | Chief Officer | Profile | |
| Joern Aldag | CEO Director | Profile | |
| Marine Popoff | Communications Mang | Profile | |
| Michael Szumera | Executive Communications | Profile | |
| Roman Necina | Chief Officer | Profile | |
| Prof MD | CoFounder | Profile | |
| Andreas Bergthaler | CoFounder | Profile | |
| Christine MBA | Chief Officer | Profile | |
| Daniel Courtney | Corporate Secretary | Profile |
About Hookipa Pharma Management Performance
The success or failure of an entity such as Hookipa Pharma often depends on how effective the management is. Hookipa Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Hookipa management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Hookipa management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.61) | (0.64) | |
| Return On Capital Employed | (1.02) | (1.07) | |
| Return On Assets | (0.61) | (0.64) | |
| Return On Equity | (0.98) | (1.03) |
Hookipa Pharma Workforce Analysis
Traditionally, organizations such as Hookipa Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Hookipa Pharma within its industry.Hookipa Pharma Manpower Efficiency
Return on Hookipa Pharma Manpower
| Revenue Per Employee | 535.9K | |
| Revenue Per Executive | 2.7M | |
| Net Loss Per Employee | 530.5K | |
| Net Loss Per Executive | 2.7M | |
| Working Capital Per Employee | 683.1K | |
| Working Capital Per Executive | 3.5M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. Market participants price Hookipa higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Hookipa Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.83) | Revenue Per Share | Quarterly Revenue Growth (0.94) | Return On Assets | Return On Equity |
Investors evaluate Hookipa Pharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Hookipa Pharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Hookipa Pharma's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Hookipa Pharma's market price signifies the transaction level at which participants voluntarily complete trades.